📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-04 15:45
10 analysed today
10
Today
133,648
All-time analysed
40,136
Positive
6,284
Negative
79,406
Neutral
7,754
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
15 announcements match the current filters (relevance ≥ 5).
9% Revenue Growth in Q1 FY27; EBITDA Rises 25% Despite European Softness
Sharda Cropchem reported a 9% YoY revenue growth to ₹1,074 Cr for Q1 FY27, supported by strong performance in LATAM and NAFTA. EBITDA grew 25% to ₹178 Cr as margins expanded by 220 bps to 16.6%, driven by a favorable product mix. However, PAT was impacted by significantly lower forex gains of ₹7.5 Cr compared to ₹73.1 Cr in the previous year. Management maintained its FY27 revenue growth guidance of 10-15% and highlighted a robust registration pipeline of 1,027 pending applications.
Confidence: HIGH
What changedThe company started FY27 with improved operational margins and a stronger cash position, despite a high base in Europe and significantly lower non-operating forex gains.
Why it mattersThe results validate the company's asset-light, registration-led model, showing that growth in LATAM and NAFTA can offset regional downturns while maintaining a debt-free balance sheet.
Q1 Revenue: ₹1,074 CrEBITDA Growth: 25%Forex Gain (Q1 FY27 vs Q1 FY26): ₹7.5 Cr vs ₹73.1 CrCash & Liquid Investments: ₹767 CrFY27 Revenue Guidance: 10-15%Cash vs Market Cap: ~10.1%
📅 Short termOperational momentum is positive with margin expansion; however, the sharp drop in net profit due to forex translation may cause short-term price volatility.
📈 Long termThe structural growth story remains intact as the company continues to invest ₹450-500 Cr annually in registrations, building a high-entry-barrier moat in regulated markets.
⚠ Risk flags
- Forex volatility impacting translation gains/losses
- Regional weather risks (e.g., European heatwaves)
- Dependency on third-party manufacturers
Key Highlights
Revenue increased 9% YoY to ₹1,074 Cr, with the Agrochemical business contributing ₹915 Cr.
EBITDA grew 25% to ₹178 Cr, with EBITDA margins expanding 220 bps to 16.6%.
Total product registrations reached 3,016 as of June 30, 2026, with 1,027 applications pending.
Cash and liquid investments increased to ₹767 Cr, up from ₹702 Cr in March 2026.
Working capital cycle improved by 10 days to 88 days compared to the previous quarter.
👀 What to Watch
Monitor the recovery in the European market, which saw temporary softening due to heatwaves, and track the conversion of the 1,027 pending registrations into revenue-generating products.
Sharda Cropchem Q1 FY27: EBITDA up 25% to ₹178 Cr; NAFTA & LATAM Offset Europe Weakness
Sharda Cropchem reported a 9% YoY revenue growth to ₹1,074 Cr for Q1 FY27, driven by robust performance in NAFTA (+33%) and LATAM (+52%) regions. While EBITDA grew 25% to ₹178 Cr with a 220 bps margin expansion to 16.6%, PAT fell 38% to ₹88 Cr due to a high base effect from forex gains in Q1 FY26. The company remains debt-free with ₹767 Cr in liquid investments and continues its asset-light strategy, investing ₹263 Cr in capex during the quarter. Management maintained its FY27 revenue growth guidance of 10-15%.
Confidence: HIGH
What changedOperational EBITDA and margins showed strong growth despite a volume dip, and the company successfully diversified its revenue base toward NAFTA and LATAM to offset European climate headwinds.
Why it mattersThe results validate the company's geographic diversification and registration-heavy model, showing that margin expansion is possible through product mix even when volumes are flat.
Revenue (Q1 FY27): ₹1,074 CrEBITDA Growth (YoY): 25%Quarterly Capex vs TTM Revenue: ~5.0%Cash and Liquid Investments: ₹767 CrAgrochemical Volume Growth: -0.60%Pending Registrations: 1,027
📅 Short termThe market is likely to view the operational EBITDA growth and margin expansion positively, looking past the optically lower PAT which was skewed by previous year's forex gains.
📈 Long termThe structural growth remains tied to the successful conversion of its massive registration pipeline into sales across regulated markets like NAFTA and Europe.
⚠ Risk flags
- Climate-related demand volatility in Europe
- Forex fluctuations impacting bottom-line consistency
- Negative volume growth in the core agrochemical segment
Key Highlights
Revenue increased 9% YoY to ₹1,074 Cr, despite a marginal 0.60% de-growth in agrochemical volumes.
EBITDA margins expanded by 220 bps to 16.6%, driven by improved product mix and high-value molecules.
Quarterly capex of ₹263 Cr represents approximately 5% of TTM revenue, focused on new product registrations.
Total product registrations reached 3,016 with 1,027 applications currently pending globally.
Europe agrochemical revenue declined 11% YoY to ₹467 Cr due to heatwaves and reduced distributor re-stocking.
👀 What to Watch
Watch for volume recovery in the high-margin European market in upcoming quarters and the execution of the 1,027 pending registrations which drive the company's asset-light growth model.
Rs 263 Cr Capex in Q1 FY27; Global Registrations Reach 3,016
Sharda Cropchem reported a significant Q1 FY27 capex of Rs 263 Cr, representing approximately 51% of the total investing activities conducted in the entire previous fiscal year (FY26). The company's core asset base of global registrations has expanded to 3,016 across 80+ countries, supported by a pipeline of 1,047 pending applications. Financial performance in FY26 showed a strong recovery with revenue at Rs 5,267.6 Cr and PAT at Rs 681 Cr, following a loss-making FY24. The company maintains an asset-light model, focusing on IP development while outsourcing manufacturing to partners, primarily in China.
Confidence: HIGH
What changedThe company has significantly accelerated its investment in intellectual property, with Q1 FY27 capex nearly matching half of the previous year's total investment.
Why it mattersFor Sharda's asset-light model, registrations are the equivalent of manufacturing capacity; this high capex signals aggressive future revenue potential and market share gains in the generic agrochemical space.
Q1 FY27 Capex: Rs 263 CrQ1 Capex vs FY26 Revenue: 4.99%Total Registrations: 3,016FY26 PAT: Rs 681.0 CrDebt-to-Equity Ratio: 0.00
📅 Short termThe high capex intensity and recovery in margins are likely to be viewed positively by the market as it indicates management's confidence in the registration-led growth strategy.
📈 Long termThe structural shift toward generic agrochemicals as patents expire provides a long-term tailwind for Sharda's library of 3,000+ registrations.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependency on third-party manufacturers in China
- Forex volatility affecting international revenue
- Pricing pressure in the generic agrochemical segment
Key Highlights
Incurred Rs 263 Cr in Capex during Q1 FY27 for new product registrations and dossiers.
Total global registrations increased to 3,016, up from 2,948 reported in late 2024.
FY26 Revenue reached Rs 5,267.6 Cr with a significantly improved EBITDA margin of 19.7%.
Maintains a debt-free balance sheet with a net worth of approximately Rs 3,137 Cr as of March 2026.
Global distribution network now spans 80+ countries with 525+ third-party distributors.
👀 What to Watch
Monitor the pace of new registration approvals in high-margin regulated markets like Europe and NAFTA, and track the impact of raw material sourcing costs from China on gross margins.
Sharda Cropchem Q1 FY27: Revenue up 9% YoY to ₹1,074 Cr, but PAT drops as margins compress
Sharda Cropchem reported a 9% YoY increase in consolidated revenue to ₹1,073.77 Cr for Q1 FY27. However, profitability faced significant headwinds as Profit Before Tax (PBT) declined 30% YoY to ₹118.43 Cr. The core Agrochemicals segment, which contributes ~85% of revenue, saw its segment result drop by 39.5% YoY to ₹82.32 Cr, indicating sharp margin contraction. Consolidated EPS for the quarter fell to ₹9.76 from ₹15.83 in the year-ago period.
Confidence: HIGH
What changedThe company transitioned into the new fiscal year with volume-led revenue growth but suffered a significant decline in operating profitability and net margins.
Why it mattersThe results highlight the vulnerability of Sharda's asset-light generic model to pricing pressure and product mix shifts, even when top-line growth is maintained. The 39.5% drop in agrochemical segment results is a material concern for short-term earnings quality.
Consolidated Revenue (Q1 FY27): ₹1,073.77 CrRevenue Growth (YoY): 9.0%Consolidated PBT: ₹118.43 CrAgrochemical Segment Margin: 9.0%Consolidated EPS: ₹9.76
📅 Short termThe stock is likely to react negatively in the short term due to the sharp contraction in margins and the year-on-year decline in PAT.
📈 Long termWhile the registration-heavy model provides a long-term moat, the company's performance remains highly sensitive to global agrochemical pricing cycles and forex volatility.
⚠ Risk flags
- Significant margin compression in core Agrochemicals segment
- High seasonality affecting quarterly performance consistency
- Limited pricing power in the generic agrochemical space
Key Highlights
Consolidated Revenue from operations grew 9.0% YoY to ₹1,073.77 Cr from ₹984.81 Cr
Consolidated Profit Before Tax (PBT) fell 30.0% YoY to ₹118.43 Cr
Agrochemicals segment result contracted to ₹82.32 Cr from ₹135.99 Cr in Q1 FY26
Non-agrochemicals segment (belts, dyes) grew 14.7% YoY to ₹158.91 Cr
Consolidated EPS for the quarter stood at ₹9.76 compared to ₹15.83 YoY
👀 What to Watch
Investors should monitor the recovery of margins in the Agrochemicals segment, which were impacted despite revenue growth. Key to watch is the management's commentary on pricing pressure in regulated markets like Europe and NAFTA, and the impact of seasonal weather patterns on the upcoming Q2 results.
Sharda Cropchem Recommends Final Dividend of Rs 9 Per Share for FY 2025-26
Sharda Cropchem Limited has announced a final dividend of Rs 9 per equity share for the financial year 2025-26. The recommendation was approved by the Board of Directors in their meeting on May 13, 2026. This dividend corresponds to a 90% payout on the face value of Rs 10 per share. The distribution is contingent upon shareholder approval at the next Annual General Meeting.
Key Highlights
Final dividend recommended at Rs 9.00 per equity share
Dividend payout is 90% of the face value of Rs 10.00
Announced for the financial year 2025-26
Subject to approval at the forthcoming Annual General Meeting
👀 What to Watch
Shareholders should hold the stock until the record date to qualify for the payout. Potential investors should evaluate the dividend yield against the current market price.
Sharda Cropchem Recommends Final Dividend of Rs 9 Per Share for FY 2025-26
Sharda Cropchem's Board of Directors has recommended a final dividend of Rs 9 per equity share for the financial year 2025-26. This dividend is based on a face value of Rs 10 per share, representing a 90% payout on the face value. The recommendation was made during the board meeting held on May 13, 2026. The final payout remains subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of Rs 9.00 per equity share for the financial year 2025-26.
The dividend payout is 90% of the face value of Rs 10.00 per share.
The board meeting for this recommendation was concluded on May 13, 2026.
Final distribution is contingent upon approval by shareholders at the forthcoming Annual General Meeting.
👀 What to Watch
Investors should track the upcoming record date to ensure eligibility for the dividend and evaluate the dividend yield against the current market price.
Sharda Cropchem Q4 FY26 PAT Jumps 57% to ₹319 Cr; EBITDA Surges 75%
Sharda Cropchem reported a robust performance for Q4 FY26, with consolidated revenue growing 13% YoY to ₹2,065 crore, primarily driven by volume growth in Europe and LATAM. The company's EBITDA surged by 75% to ₹513 crore as gross margins expanded significantly by 750 basis points to 37.3%. For the full year FY26, revenue reached ₹5,268 crore, marking a 22% increase, led by a 25% growth in the core agrochemical segment. The company continues to leverage its asset-light model, investing ₹505 crore in capex during FY26, largely for product registrations.
Key Highlights
Q4 FY26 consolidated revenue increased 13% YoY to ₹2,065 Cr, with Agrochemicals contributing 93% of total sales.
EBITDA for the quarter grew 75% YoY to ₹513 Cr, with EBITDA margins improving to 24.8%.
Gross margins expanded by 750 bps to 37.3% in Q4, with management expecting these levels to sustain in FY27.
Full-year FY26 revenue stood at ₹5,268 Cr, a 22% increase over the previous financial year.
The company holds 3,011 global registrations with an additional 1,004 applications currently pending.
👀 What to Watch
Investors should view the significant margin expansion and strong volume growth in Europe as positive indicators of operational efficiency. The company's focus on an asset-light model and a growing registration pipeline supports long-term scalability, though the slight decline in NAFTA agrochemical revenue should be monitored.
Sharda Cropchem FY26 PAT Surges 124% to ₹681 Cr; Total Dividend at ₹15 Per Share
Sharda Cropchem reported a stellar performance for FY26, with annual revenue growing 22% to ₹5,268 crore and PAT more than doubling to ₹681 crore. The company's EBITDA margins saw a significant expansion from 14.2% to 19.7%, driven by improved product mix and volume growth in the agrochemical segment. A final dividend of ₹9 per share has been recommended, bringing the total FY26 payout to ₹15. The company maintains a debt-free balance sheet with a robust cash position of ₹702 crore and a record RoCE of 30.4%.
Key Highlights
FY26 Net Profit (PAT) increased by 124% YoY to ₹681 crore, while Q4 PAT rose 57% to ₹319 crore.
Consolidated EBITDA for FY26 grew 69% to ₹1,040 crore with margins expanding significantly to 19.7%.
Agrochemical segment revenue grew 25% YoY in FY26, with Europe showing the strongest regional growth at 37%.
Achieved highest-ever Return on Capital Employed (RoCE) of 30.4% and remains debt-free with ₹702 crore in liquid assets.
Recommended a final dividend of ₹9 per share, taking the total FY26 dividend to ₹15 per share.
👀 What to Watch
The stock is expected to react very positively to the massive margin expansion and doubling of profits. Investors should monitor the company's ability to convert its 1,004 pending registrations into revenue as it continues its asset-light growth strategy.
Sharda Cropchem Recommends ₹9.00 Final Dividend and Approves FY26 Audited Results
Sharda Cropchem Limited has announced its audited financial results for the year ended March 31, 2026, alongside a final dividend recommendation of ₹9.00 per share. The company's 26 subsidiaries showed robust performance, contributing ₹2,80,239 lakhs in revenue and ₹21,070 lakhs in net profit. The statutory auditors, B S R & Co. LLP, have issued a clean audit report with no qualifications. This announcement reflects stable financial health and a commitment to shareholder returns.
Key Highlights
Recommended a final dividend of ₹9.00 per equity share of ₹10.00 face value.
Subsidiaries contributed a total revenue of ₹2,80,239 lakhs for the financial year.
Net profit after tax from subsidiaries reported at ₹21,070 lakhs.
Total assets across 26 audited subsidiaries amounted to ₹1,67,737 lakhs.
Statutory auditors issued an unqualified opinion on both standalone and consolidated results.
👀 What to Watch
The ₹9.00 dividend provides a tangible return; investors should hold for the dividend record date. The clean audit report and subsidiary performance indicate strong operational control.
Sharda Cropchem Q3 FY26 PAT Surges 366% to ₹145 Cr; Declares ₹6 Interim Dividend
Sharda Cropchem reported a stellar Q3 FY26 performance with revenue growing 39% YoY to ₹1,289 crores, driven by a 48% surge in the agrochemical segment. Profitability saw a massive jump as PAT rose 366% to ₹145 crores, marking the company's highest-ever annual PAT within just nine months. Management has guided for continued momentum in FY27 with expected volume growth of 15% and revenue growth of 15-20%. The company remains net debt-free with a strong cash position of ₹826 crores and has declared an interim dividend of ₹6 per share.
Key Highlights
Q3 FY26 Revenue grew 39% YoY to ₹1,289 crores, with Agrochemicals segment growing 48%
PAT witnessed a massive 366% YoY growth to ₹145 crores, achieving record annual PAT in 9 months
EBITDA margins improved to 19.1%, with management raising FY26 guidance to the 18-20% range
Working capital cycle improved significantly by 48 days compared to March 2025, now at 70 days
Total product registrations reached 3,004, with an additional 1,076 applications in the pipeline
👀 What to Watch
Investors should note the strong volume recovery in Europe and Latin America and the company's ability to pass on costs. The robust registration pipeline and asset-light model support the management's optimistic 15-20% revenue growth guidance for FY27.
Sharda Cropchem Q3 PAT Jumps 366% to ₹145 Cr; Record 9M Profit; ₹6 Dividend Declared
Sharda Cropchem reported a stellar Q3 FY26 with revenue growing 39% YoY to ₹1,288.8 crore, driven by strong volume growth in Europe. Net profit skyrocketed by 366% YoY to ₹145.1 crore, while EBITDA margins expanded by 250 bps to 19.1%. Notably, the company has already achieved its highest-ever annual PAT within the first nine months of the fiscal year, totaling ₹362.3 crore. The company remains debt-free with a strong cash position of ₹826 crore and has declared an interim dividend of ₹6 per share.
Key Highlights
Revenue grew 39% YoY to ₹1,288.8 Cr in Q3 FY26, with 9M FY26 revenue up 29% to ₹3,202.7 Cr.
PAT for Q3 surged 366% YoY to ₹145.1 Cr; 9M FY26 PAT of ₹362.3 Cr is already the highest-ever annual profit for the company.
EBITDA margins improved to 19.1% in Q3, up from 16.6% YoY, driven by volume growth and improved product mix.
Europe agrochemical revenue grew by 123% YoY in Q3, significantly offsetting a 7% decline in the NAFTA region.
Company declared an interim dividend of ₹6 per share and remains debt-free with ₹826 Cr in liquid investments.
👀 What to Watch
Investors should view this as a very strong performance characterized by significant margin expansion and record profits. The stock is likely to react positively to the earnings beat and the healthy interim dividend payout.
Sharda Cropchem Q3 FY26 PAT Surges 366% YoY to ₹145 Cr; Revenue Up 39%
Sharda Cropchem reported a robust performance for Q3 FY26, with total revenue growing 39% YoY to ₹1,289 crore, primarily driven by a 48% surge in the agrochemical segment. Net profit (PAT) witnessed a massive jump of 366% to ₹145 crore, supported by a 220 bps improvement in gross margins to 34.9%. The growth was largely fueled by the European market, which saw a 123% revenue increase in the agrochemical division. The company continues its asset-light strategy, investing ₹399 crore in capex during 9M FY26, mainly for product registrations.
Key Highlights
Consolidated Revenue for Q3 FY26 grew 39% YoY to ₹1,289 Cr, with Agrochemicals contributing 89% of total sales.
Net Profit (PAT) skyrocketed 366% YoY to ₹145 Cr, while EBITDA rose 59% to ₹246 Cr during the quarter.
Gross Margins expanded by 220 basis points to 34.9% due to a favorable product mix and 14.5% volume growth in Agrochemicals.
European agrochemical revenue more than doubled, growing 123% YoY to ₹654 Cr, offsetting a 7% decline in the NAFTA region.
The company maintains a strong IP pipeline with 3,004 registrations and 1,076 additional applications pending globally.
👀 What to Watch
Investors should take note of the significant margin expansion and the company's successful penetration in the European market. The asset-light model continues to deliver high returns, making it a strong play in the global generic agrochemical space.
Sharda Cropchem Q3 Net Profit Jumps 366% YoY to ₹145 Cr; Declares ₹6 Dividend
Sharda Cropchem reported a robust performance for Q3 FY26, with consolidated revenue from operations rising 38.7% YoY to ₹1,288.76 crore. The company's net profit saw a massive surge of 366% YoY, reaching ₹145.11 crore compared to ₹31.14 crore in the same quarter last year. Additionally, the board declared an interim dividend of ₹6.00 per equity share, with a record date of February 6, 2026. This strong performance is reflected in the 9-month FY26 profit, which has more than tripled to ₹362.27 crore compared to the previous year.
Key Highlights
Revenue from operations increased 38.7% YoY to ₹1,288.76 crore in Q3 FY26
Consolidated Net Profit rose significantly to ₹145.11 crore from ₹31.14 crore in Q3 FY25
Interim dividend of ₹6.00 per share (60% of face value) declared for FY 2025-26
9-month FY26 Net Profit stands at ₹362.27 crore versus ₹100.81 crore in 9M FY25
Foreign exchange loss narrowed to ₹4.54 crore in Q3 FY26 from ₹39.51 crore in Q3 FY25
👀 What to Watch
The stock is expected to react positively to the substantial growth in both top and bottom lines along with the dividend payout. Investors may consider holding or accumulating on dips given the strong 9-month performance momentum.
Sharda Cropchem Sets February 6, 2026, as Record Date for Interim Dividend
Sharda Cropchem Limited has officially fixed Friday, February 6, 2026, as the record date for its interim dividend for the financial year 2025-26. This date will be used to determine the eligibility of shareholders to receive the dividend payment. The announcement follows the company's compliance with SEBI Listing Obligations and Disclosure Requirements. While the specific dividend amount was not detailed in this filing, the establishment of a record date confirms a forthcoming cash payout to eligible investors.
Key Highlights
Record date for interim dividend fixed as February 6, 2026
Dividend pertains to the Financial Year 2025-26
Announcement made in compliance with Regulation 42 of SEBI LODR Regulations
Applies to shareholders of NSE: SHARDACROP and BSE: 538666
👀 What to Watch
Investors seeking to receive the dividend should ensure they hold the stock before the ex-dividend date, which typically precedes the record date. Current shareholders must maintain their positions through the record date to qualify for the payout.
Sharda Cropchem Q3 Net Profit Surges 366% YoY to ₹145.1 Cr; Declares ₹6 Interim Dividend
Sharda Cropchem reported a robust Q3 FY26 with consolidated revenue rising 38.7% YoY to ₹1,288.76 crore. Net profit saw a massive jump of 366% YoY to ₹145.11 crore, driven by strong operational performance and significantly lower foreign exchange losses compared to the previous year. The board also declared an interim dividend of ₹6 per share (60% of face value) with a record date of February 6, 2026. For the nine-month period ended December 2025, the company has already surpassed its full-year FY25 profit, reaching ₹362.27 crore.
Key Highlights
Q3 FY26 Consolidated Revenue grew 38.7% YoY to ₹1,288.76 crore.
Net Profit for the quarter jumped 366% YoY to ₹145.11 crore from ₹31.14 crore in Q3 FY25.
Interim dividend of ₹6.00 per share declared; Record date set for February 6, 2026.
9M FY26 Net Profit reached ₹362.27 crore, a 259% increase over the 9M FY25 period.
Foreign exchange losses reduced significantly to ₹4.54 crore in Q3 FY26 from ₹39.51 crore YoY.
👀 What to Watch
The stock is likely to react positively to the massive profit growth and dividend payout. Investors should consider holding or accumulating on dips as the company shows strong operational recovery and margin improvement.
